Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS +1.72% Equity-to-Asset is 0.90 as of Dec. 2025, which is 1% below its 10-year median of 0.91. The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 94.81% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Genetic Signatures's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$44.09 Mil. Genetic Signatures's Total Assets for the quarter that ended in Dec. 2025 was A$49.04 Mil.
Therefore, Genetic Signatures's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.90.
The historical rank and industry rank for Genetic Signatures's Equity-to-Asset or its related term are showing as below:
ASX:GSS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.76 Med: 0.91 Max: 0.95
Current: 0.9
During the past 11 years, the highest Equity to Asset Ratio of Genetic Signatures was 0.95. The lowest was 0.76. And the median was 0.91.
ASX:GSS's Equity-to-Asset is ranked better than 94.81% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs ASX:GSS: 0.90
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Genetic Signatures Equity-to-Asset Related Terms
Genetic Signatures Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Genetic Signatures's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a Equity-to-Asset of 0.90 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Genetic Signatures and its competitors. This is near median its historical median of 0.91. Over the past decade, Genetic Signatures' Equity-to-Asset has ranged from 0.76 to 0.95. According to the industry distribution chart, Genetic Signatures ranks #11 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 5.2%.
Is Genetic Signatures' Equity-to-Asset too high?
Genetic Signatures' current Equity-to-Asset of 0.90 is near median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 0.95. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Genetic Signatures' value of 0.90 is 52.5% above this industry median. Based on the distribution chart, Genetic Signatures ranks #11 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #11 out of 212 companies for Equity-to-Asset. This places Genetic Signatures in the top 5% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.59. Genetic Signatures' value of 0.90 is 52.5% above this benchmark. Historically, Genetic Signatures' own Equity-to-Asset has ranged from 0.76 to 0.95 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.59, Genetic Signatures has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current Equity-to-Asset of 0.90 is 52.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current Equity-to-Asset is 0.90, which is near median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.06 — trading 84.5% below its estimated fair value. The current Equity-to-Asset is 0.90, which is near median its 10-year median of 0.91 and 52.5% above the Medical Diagnostics & Research industry median of 0.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Equity-to-Asset is 0.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
